细胞角蛋白20在膀胱癌中的研究进展

膀胱肿瘤是最常见的泌尿系统肿瘤，其中上皮性肿瘤占95％以上，绝大多数为尿路移行上皮细胞癌。膀胱癌的早期症状不明显，复发率较高，早期诊断和治疗对提高其疗效非常重要。近年来，诊断膀胱肿瘤的新方法不断出现，显著提高了膀胱肿瘤诊断及预后预测水平。其中，膀胱肿瘤标记物检测已成为膀胱肿瘤的诊断新方法，具有十分重要的临床意义。研究发现，细胞角蛋白20fcytokeratin20，CK20）是中间纤维家族成员之一，在正常膀胱组织中特异性表达于伞细胞，在膀胱癌中特异性表达于膀胱移行细胞癌，其诊断膀胱肿瘤的特异性和灵敏性均较高，且与膀胱肿瘤的临床分级、病理分期和转移均密切相关，因此可作为辅助诊断膀胱肿瘤的检测标志物及治疗和预后评估指标。本文将就其在膀胱癌中的研究进展综述如下。

Research Progress on Cytokeratin 20 in Bladder Cancer

Bladder tumors were the most common tumors of the urinary system, accounting for more than 95% of epithelial tumors, the vast majority were urinary tract transitional cell carcinoma. The early symptoms of bladder cancer were unobvious, and the recurrence rate was high, early diagnosis and treatment were very important to improve its efficacy. In recent years, new diagnosis of bladder cancer was emerging, significantly improved the diagnosis and prognosis prediction level of bladder tumor. Markers detection of bladder tumor had become a new method for the diagnosis of bladder tumors, which had important clinical significance. It was found that cytokeratin 20 （CK20） was one of the members of the family of intermediate filaments, which specifically expressed in umbrella cells of normal bladder tissue as well as bladder transitional cell carcinoma. It had high specificity and sensitivity of diagnosis of bladder cancer, and was closely related to the clinical grade, pathologic stage and metastasis of bladder tumor. So it could be used as a marker for the diagnosis and prediction of prognosis of bladder tumor. This article summarized the research progress on cytokeratin 20 in bladder cancer.